Connect with us

Hi, what are you looking for?

DOGE0.070.84%SOL19.370.72%USDC1.000.01%BNB287.900.44%AVAX15.990.06%XLM0.080.37%
USDT1.000%XRP0.392.6%BCH121.000.75%DOT5.710.16%ADA0.320.37%LTC85.290.38%
THE BIZNOB – Global Business & Financial News – A Business Journal – Focus On Business Leaders, Technology – Enterpeneurship – Finance – Economy – Politics & LifestyleTHE BIZNOB – Global Business & Financial News – A Business Journal – Focus On Business Leaders, Technology – Enterpeneurship – Finance – Economy – Politics & Lifestyle

Finance

Finance

Bayer one step closer to acquiring Monsanto

There’s about to be a new monopoly in town

German pharmaceutical company Bayer launched a cash call for 6 billion euros ($7 billion) to finance the acquisition of seed and pesticide manufacturer Monsanto. The deal estimates at around $62.5 billion (!!!).

Last week, Bayer received approval from the US for the acquisition, which was one of their biggest hurdles. Although this deal will create the largest pesticide company in the world by an enormous margin, the Department of Justice did not deem the deal as violating any antitrust laws.

And although the cash call won’t be enough to secure the deal, Bayer is taking other measures to ensure it acquires the seed company. Further, they sold a good chunk of their stake in plastic manufacturer Covestro, which supplied them with 4.5 billion euros. The firm also sold assets to German chemical producer BASF for 7.6 billion euros.

According to Bayer’s executives, they are close enough to close the deal, which will supposedly close on Thursday. Moreover, they must stay true to this deadline, for Monsanto will pull out of the deal after June 14thand raise the asking price.

Forecasting their earnings based on their 2017 sales, Bayer will produce 20 billion euros worth of agricultural products. The next leading competitors, Corteva Agriscience and Syngenta, will make roughly 12.4 and 7.9 billion euros, respectively.

This acquisition has no small asking price, but clearly, the deal will show immediate returns for Bayer. The competition will have significant work to do if this deal goes through.

 

Featured image via Flickr/Conan


Comment Template

You May Also Like

Business

Bayer has prevailed in a trial. A Californian man who claimed to have developed cancer as a result of exposure to the company’s Roundup...

Economy

Bayer (BAYGn.DE) had a call with investors on Monday after a spate of negative news caused some of them to question whether the German...

Business

Bayer ordered to pay $1.56 billion in latest US trial loss over Roundup weedkiller. Four plaintiffs claimed that Bayer’s Roundup weedkiller caused injuries, including...

Business

Bayer stopped the blood thinner drug trial for lack of effect, a major setback. Germany’s Bayer (BAYGn.DE) canceled a significant late-stage experiment testing a...

Notice: The Biznob uses cookies to provide necessary website functionality, improve your experience and analyze our traffic. By using our website, you agree to our Privacy Policy and our Cookie Policy.

Ok